Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Global Blood Therapeutics, Inc.

http://www.globalbloodtx.com/index.php

Latest From Global Blood Therapeutics, Inc.

S&E Briefs: The Good and The Bad Of COVID-19 On Biotech's Top Line

Regeneron's COVID-19 antibody cocktail helped drive 38% growth for the company, while Global Blood Therapeutics' Oxbryta continues to face headwinds and Horizon focuses on relaunches.

Sales & Earnings Launches

GBT Bucks Gene Therapy Trend With Sanofi Sickle Cell Deal

Building on Oxbryta, which is already approved in the US for the rare blood disorder, Global Blood Therapeutics has licensed two sickle cell disease programs from Sanofi.

Blood & Coagulation Disorders Deals

Five New EU Filings Leave Starting Blocks at EMA

There is one orphan drug among the five new marketing authorization applications that the European Medicines Agency has under review. All five drugs will be reviewed under standard review timelines.

Europe Review Pathway

Novartis and Gates Foundation Ink Sickle Cell Gene Therapy Pact

The Swiss major envisions developing an accessible in vivo gene therapy for SCD that could potentially be administered once directly to the patient without the need to modify cells in a lab.

Gene Therapy Blood & Coagulation Disorders
See All

Company Information

UsernamePublicRestriction

Register